公开(公告)号：US12151025B2

公开(公告)日：2024-11-26

申请号：US18120596

申请日：2023-03-13

Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.

Inventor： Shuichi Endo ,  Naoya Yoshioka

IPC: A61K9/19 ,  A61K31/734 ,  A61K47/02 ,  A61K47/36 ,  A61L27/00 ,  C08B37/00

Abstract: The present invention provides: a freeze-dried composition which comprises (a) a monovalent metal alginate and (b) a salt selected from a monovalent metal salt and an ammonium salt; and a method of producing a freeze-dried monovalent metal alginate composition which comprises the steps of freezing an aqueous solution formed by dissolving at least the component (a) and the component (b), performing first drying, and then performing second drying as desired to reduce a water content to 3% by mass or less. This is a freeze-dried monovalent metal alginate composition with suppressed viscosity decrease with the lapse of time.

公开(公告)号：US12102734B2

公开(公告)日：2024-10-01

申请号：US17239322

申请日：2021-04-23

Applicant: THE TRUSTEES OF INDIANA UNIVERSITY

Inventor： Alexander Gumennik ,  Louis Alexandre van der Elst ,  Merve Gokce Kurtoglu

IPC: A61L27/00 ,  A61L27/04 ,  A61L27/36 ,  A61L27/38 ,  A61L27/50 ,  B33Y80/00 ,  A61L27/14

CPC classification number: A61L27/3839 ,  A61L27/04 ,  A61L27/3633 ,  A61L27/50 ,  B33Y80/00 ,  A61L27/14 ,  A61L2300/414 ,  A61L2420/04 ,  A61L2420/08

Abstract: A method of producing bioengineered tissue includes coating a microstructured fiber with a bioink containing a plurality of living cells. The microstructured fiber is embedded with microfluidic channels defining periodic outlet apertures, a plurality of ultrasonic transducers, at least one chemical sensor, and at least one temperature sensor. The method further includes applying the coated fiber to an anatomic model of an organ. The microfluidic channels and outlet apertures of the fiber are configured to function as an artificial blood-vessel system to the bioengineered tissue, thereby supplying building material for the proliferation of the plurality of living cells, and allowing the bioengineered tissue to mature into functional tissue.

公开(公告)号：US12029831B2

公开(公告)日：2024-07-09

申请号：US18089047

申请日：2022-12-27

Applicant: CORONADO AESTHETICS, LLC ,  nanoComposix, Inc.

Inventor： Steven J. Oldenburg ,  Martin Miranda ,  David S. Sebba ,  Todd J. Harris

IPC: C09D129/04 ,  A61K9/51 ,  A61K33/38 ,  A61K47/24 ,  A61K47/32 ,  A61L27/00 ,  B22F1/054 ,  B22F1/0545 ,  B22F1/14 ,  B22F1/145 ,  B22F1/16 ,  C08J3/205 ,  C08K3/08 ,  C08K3/28 ,  C08K3/36 ,  C08K3/38 ,  C08K5/092 ,  C08K5/1535 ,  C09D125/06 ,  C09D139/06 ,  B22F1/068

CPC classification number: A61L27/00 ,  A61K9/5115 ,  A61K9/5123 ,  A61K9/5138 ,  A61K33/38 ,  A61K47/24 ,  A61K47/32 ,  B22F1/0545 ,  B22F1/0551 ,  B22F1/14 ,  B22F1/145 ,  B22F1/147 ,  B22F1/16 ,  C08J3/2053 ,  C08K3/08 ,  C08K3/28 ,  C08K3/36 ,  C08K3/38 ,  C08K5/092 ,  C08K5/1535 ,  C09D125/06 ,  C09D129/04 ,  C09D139/06 ,  A61L2300/104 ,  B22F1/068 ,  B22F2301/255 ,  B22F2998/10 ,  C08J2325/18 ,  C08J2329/04 ,  C08K2003/0806

Abstract: Embodiments of the present invention relate to methods for preparing high optical density solutions of nanoparticle, such as nanoplates, silver nanoplates or silver platelet nanoparticles, and to the solutions and substrates prepared by the methods. The process can include the addition of stabilizing agents (e.g., chemical or biological agents bound or otherwise linked to the nanoparticle surface) that stabilize the nanoparticle before, during, and/or after concentration, thereby allowing for the production of a stable, high optical density solution of silver nanoplates. The process can also include increasing the concentration of silver nanoplates within the solution, and thus increasing the solution optical density.

公开(公告)号：US20230113828A1

公开(公告)日：2023-04-13

申请号：US18077947

申请日：2022-12-08

Applicant: GID Bio, Inc.

Inventor： William W. Cimino ,  Ramon Llull ,  Adam J. Katz

IPC: C12M1/00 ,  C12M1/33 ,  A61L27/00 ,  A61K35/32 ,  C12N5/077

Abstract: Harvested adipose tissue is processed in a single-use portable processing container to prepare a centrifuges pellet phase of stromal vascular fraction concentrate, which is selectively removed and disposed in a syringe dispersed in a dispersion medium to prepare an osteoarthritis treatment product.

公开(公告)号：US11564790B2

公开(公告)日：2023-01-31

申请号：US16601503

申请日：2019-10-14

Applicant: Mariela Aguilar

Inventor： Mariela Aguilar

IPC: A61L27/00 ,  A61L27/38 ,  A61F2/10 ,  A61L27/60 ,  A61L27/24 ,  A61L27/48 ,  A61L27/54 ,  B33Y10/00 ,  A61F2/28 ,  A61F2/30 ,  B33Y80/00 ,  G06T7/73

Abstract: A method includes forming a scaffold and seeding the scaffold with live cells; growing the cells in the scaffold; and 3D printing the cells into a living subject, where the cells continue to live in the living subject.

公开(公告)号：US11554195B2

公开(公告)日：2023-01-17

申请号：US15739555

申请日：2016-06-22

Applicant: Cedars-Sinai Medical Center

Inventor： Zulma Gazit ,  Dmitriy Sheyn ,  Gadi Pelled ,  Dan Gazit

IPC: C12N5/00 ,  A61L27/00 ,  A61L27/38 ,  A61L27/22 ,  A61L27/52 ,  C12N5/077

Abstract: Described herein are compositions and methods related to derivation of human notochordal cells differentiated from induced pluripotent stem cells (iPSCs). The inventors have developed a two-step process for generating these iPSC-derived notochordal cells (iNCs), which can provide a renewable source of therapeutic material for use in degenerative disc disease (DDD). As iNCs are capable of reversing DDD and supporting regeneration of intervertebral disc (IVD) tissue based on the understanding that NC cells maintain homeostasis and repair of other IVD cell types such as nuclear pulposus (NP).

公开(公告)号：US20220340760A1

公开(公告)日：2022-10-27

申请号：US17810049

申请日：2022-06-30

Applicant: Johnson & Johnson Vision Care, Inc.

Inventor： Derek Nankivil ,  Shivkumar Mahadevan ,  Dawn D. Wright

IPC: C09B62/465 ,  G02B1/04 ,  C08L83/04 ,  C08L77/00 ,  A61L27/00 ,  G02C7/04 ,  G02C7/10 ,  C08F230/08

Abstract: Described are polymerizable high energy light absorbing compounds. The compounds absorb various wavelengths of ultraviolet and/or high energy visible light and are suitable for incorporation in various products, such as biomedical devices and ophthalmic devices.

公开(公告)号：US20220340759A1

公开(公告)日：2022-10-27

申请号：US17809619

申请日：2022-06-29

Applicant: Johnson & Johnson Vision Care, Inc.

Inventor： Donald E. Riederer ,  Patricia Martin ,  Shivkumar Mahadevan ,  Dawn D. Wright ,  John R. Buch ,  Jessica Cannon

IPC: C09B62/465 ,  G02B1/04 ,  C08L83/04 ,  C08L77/00 ,  A61L27/00 ,  G02C7/04 ,  G02C7/10 ,  C08F230/08

Abstract: Described are polymerizable high energy light absorbing compounds. The compounds absorb various wavelengths of ultraviolet and/or high energy visible light and are suitable for incorporation in various products, such as biomedical devices and ophthalmic devices. Such devices exhibit a number of desirable properties, including favorable rates of pervaporation.

公开(公告)号：US11452796B2

公开(公告)日：2022-09-27

申请号：US16625457

申请日：2018-06-29

Applicant: AlloSource

Inventor： Reginald Stilwell ,  Ramasamy Sakthivel ,  William Maslanik

IPC: A61L27/00 ,  A61L27/36 ,  A61L27/22 ,  A61L27/38

Abstract: The disclosure provides bone graft materials, methods for their use and manufacture. Exemplary bone graft materials comprise combining a radiopaque component with a cancellous bone component to produce a bone graft material, wherein the cancellous bone component comprises native osteoreparative cells. Methods for treating a subject with the bone graft material are also provided.

公开(公告)号：US20210002328A1

公开(公告)日：2021-01-07

申请号：US16750742

申请日：2020-01-23

Applicant: Allegro Pharmaceuticals, LLC

Inventor： Michael John Mackel ,  John Y. Park ,  Hampar L. Karageozian ,  Vicken H. Karageozian

IPC: C07K5/09 ,  A61K47/64 ,  A61K51/08 ,  C07K7/06 ,  C07K7/64 ,  A61K9/08 ,  A61K38/17 ,  A61K51/06 ,  A61L26/00 ,  A61L27/00 ,  A61L27/22 ,  A61L31/04 ,  G01N1/00 ,  A61K38/06 ,  A61K38/08 ,  A61K38/12 ,  A61K39/395

Abstract: Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting integrins including but not necessarily limited to α5β1-Integrin, αvβ3-Integrin and αvβ5-Integrin, inhibiting cellular adhesion to RGD binding sites, preventing or treating viral or other microbial infections, inhibiting angiogenesis in tumors, retinal tissue or other tissues or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.